Scaling basic toxicokinetic parameters from rat to man

被引:70
作者
Bachmann, K
Pardoe, D
White, D
机构
关键词
half-life; humans; pharmacokinetics; rats; scaling toxicokinetics; volume of distribution;
D O I
10.2307/3432684
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Scaling of the quantified dispositional parameters of xenobiotics from animals to man is of interest from the standpoint of toxicology (e.g., poisoning and risk assessment). Scaling is also important from the standpoint of therapeutics because it represents a strategy for predicting first-use-in-human doses in clinical trials of investigational new drugs. Current strategies for scaling either doses of xenobiotics or the dispositional parameters of xenobiotics from animals to man rely on models that take account principally of species differences in weight or body surface area Interspecies scaling of dispositional parameters such as clearance or volume of distribution commonly involves the comparison of estimates of these parameters for a given xenobiotic among numerous species On the basis of weight with the resultant mathematical relationship used to predict the values of those parameters for that xenobiotic in a species weighing, on average, about 70 kg (i.e., a man). Our approach has been to ascertain whether a useful mathematical model could be developed for predicting the dispositional parameters of a xenobiotic, its half-life and volume of distribution, in humans based exclusively on estimates of those parameters in rats. Based on a data set of about 100 different xenobiotics, we found that values for half-life and volume of distribution of a xenobiotic in humans can be predicted from the estimates of those parameters in rats.
引用
收藏
页码:400 / 407
页数:8
相关论文
共 146 条
[1]   A POPULATION ANALYSIS OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MIDAZOLAM IN THE RAT [J].
AARONS, L ;
MANDEMA, JW ;
DANHOF, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (05) :485-496
[2]   DOSE-DEPENDENT PHARMACOKINETICS OF CIMETIDINE IN THE RAT [J].
ADEDOYIN, A ;
AARONS, L ;
HOUSTON, JB .
XENOBIOTICA, 1987, 17 (05) :595-604
[3]  
ADUSUMALLI VE, 1991, DRUG METAB DISPOS, V19, P1116
[4]  
Andersen M E, 1992, Arch Toxicol Suppl, V15, P217
[5]  
BACHMANN K, 1986, INT J CLIN PHARM TH, V24, P546
[6]   INVIVO EVIDENCE THAT ETHOSUXIMIDE IS A SUBSTRATE FOR CYTOCHROME-P450IIIA [J].
BACHMANN, K ;
CHU, CA ;
GREEAR, V .
PHARMACOLOGY, 1992, 45 (03) :121-128
[7]   USING SINGLE CLEARANCE ESTIMATES TO PROBE HEPATIC DRUG-METABOLISM IN RATS - ETHOSUXIMIDE DISPOSITION KINETICS IN RATS [J].
BACHMANN, K ;
JAHN, D ;
YANG, C ;
SCHWARTZ, J .
XENOBIOTICA, 1988, 18 (04) :373-380
[8]   DISPOSITIONAL AND PHARMACODYNAMIC CHARACTERISTICS OF BRODIFACOUM IN WARFARIN-SENSITIVE RATS [J].
BACHMANN, KA ;
SULLIVAN, TJ .
PHARMACOLOGY, 1983, 27 (05) :281-288
[9]  
BAGGOT JD, 1994, AM J VET RES, V55, P689
[10]   ABSORPTION AND ELIMINATION OF METOCLOPRAMIDE IN 3 ANIMAL SPECIES [J].
BAKKE, OM ;
SEGURA, J .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1976, 28 (01) :32-39